Base de dados : MEDLINE
Pesquisa : D02.033.800.609.500 [Categoria DeCS]
Referências encontradas : 50 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 5 ir para página              

  1 / 50 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:22641263
[Au] Autor:Kovács P
[Ad] Endereço:pkovacs@med.unideb.hu
[Ti] Título:[Tibor Vályi-Nagy (1912-1969), professor and researcher of pharmacology, was born one hundred years ago].
[Ti] Título:Száz éve született Vályi-Nagy Tibor (1912-1969), a gyógyszertan kutató professzora..
[So] Source:Orv Hetil;153(22):869-72, 2012 Jun 03.
[Is] ISSN:0030-6002
[Cp] País de publicação:Hungary
[La] Idioma:hun
[Mh] Termos MeSH primário: Docentes de Medicina/história
Macrolídeos/história
Mitobronitol/história
Farmacologia/história
Pesquisadores/história
Faculdades de Farmácia/história
[Mh] Termos MeSH secundário: Academias e Institutos/história
Antineoplásicos Alquilantes/história
História do Século XX
Seres Humanos
Hungria
Macrolídeos/farmacologia
Farmacologia/educação
Sistemas Políticos/história
Política
Faculdades de Farmácia/organização & administração
[Pt] Tipo de publicação:BIOGRAPHY; HISTORICAL ARTICLE; JOURNAL ARTICLE; PORTRAITS
[Ps] Nome de pessoa como assunto:Vályi-Nagy T
[Nm] Nome de substância:
0 (Antineoplastic Agents, Alkylating); 0 (Macrolides); 5UP30YED7N (Mitobronitol); M3Y14N50DX (primycin)
[Em] Mês de entrada:1207
[Cu] Atualização por classe:151119
[Lr] Data última revisão:
151119
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:120530
[St] Status:MEDLINE
[do] DOI:10.1556/OH.2012.HO2411


  2 / 50 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:17189221
[Au] Autor:Tanaka Y; Nagai Y; Mori M; Fujita H; Togami K; Kurata M; Matsushita A; Maeda A; Nagai K; Tanaka K; Takahashi T
[Ad] Endereço:Department of Hematology and Clinical Immunology, Kobe City General Hospital, Kobe, Japan.
[Ti] Título:Multiple granulocytic sarcomas in essential thrombocythemia.
[So] Source:Int J Hematol;84(5):413-6, 2006 Dec.
[Is] ISSN:0925-5710
[Cp] País de publicação:Japan
[La] Idioma:eng
[Ab] Resumo:A 59-year-old woman was diagnosed with essential thrombocythemia in 1988 and had been treated with hydroxyurea, mitobronitol, busulfan, and ranimustine, in that order. Hepatosplenomegaly, low-grade fever, and body weight loss manifested, and a few blasts were noted in the peripheral blood studied in March 2002. A biopsied specimen of the bone marrow showed myelofibrosis but not a leukemia in August 2004. An abnormal karyotype with der(1; 13) appeared for the first time. She was treated with low-dose prednisolone. In January 2005, she experienced left hip joint pain, and magnetic resonance scanning showed a tumoral lesion in the femoral head. Histological diagnosis of the biopsied mass revealed that it was a granulocytic sarcoma, and radiotherapy was performed. In April 2005, bone scintigraphy showed multiple lesions. She became febrile and red blood cell transfusion-dependent with hepatosplenomegaly and a small number of circulating blasts. Intravenous cytarabine (low dose) and etoposide relieved the fever and hepatosplenomegaly; however, she developed a pathologic fracture of the right humerus. An additional karyotypic abnormality (7q22 deletion) was noted. She subsequently died of infection. Granulocytic sarcoma is very rare in essential thrombocythemia, and this patient may be the first reported case of essential thrombocythemia that developed multiple lesions and a pathologic fracture without transformation to overt leukemia.
[Mh] Termos MeSH primário: Neoplasias Femorais
Mielofibrose Primária
Sarcoma Mieloide
Trombocitemia Essencial/complicações
[Mh] Termos MeSH secundário: Protocolos de Quimioterapia Combinada Antineoplásica/administração & dosagem
Protocolos de Quimioterapia Combinada Antineoplásica/efeitos adversos
Transfusão de Sangue
Deleção Cromossômica
Cromossomos Humanos Par 7
Citarabina/administração & dosagem
Etoposídeo/administração & dosagem
Evolução Fatal
Feminino
Fraturas do Fêmur/diagnóstico por imagem
Fraturas do Fêmur/etiologia
Fraturas do Fêmur/genética
Fraturas do Fêmur/patologia
Fraturas do Fêmur/terapia
Neoplasias Femorais/diagnóstico por imagem
Neoplasias Femorais/etiologia
Neoplasias Femorais/genética
Neoplasias Femorais/patologia
Neoplasias Femorais/terapia
Seres Humanos
Hidroxiureia/administração & dosagem
Hidroxiureia/efeitos adversos
Meia-Idade
Mitobronitol/administração & dosagem
Mitobronitol/efeitos adversos
Metástase Neoplásica
Compostos de Nitrosoureia/administração & dosagem
Compostos de Nitrosoureia/efeitos adversos
Mielofibrose Primária/diagnóstico por imagem
Mielofibrose Primária/etiologia
Mielofibrose Primária/genética
Mielofibrose Primária/patologia
Mielofibrose Primária/terapia
Radiografia
Sarcoma Mieloide/diagnóstico por imagem
Sarcoma Mieloide/genética
Sarcoma Mieloide/patologia
Sarcoma Mieloide/terapia
Trombocitemia Essencial/tratamento farmacológico
Trombocitemia Essencial/patologia
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Nitrosourea Compounds); 04079A1RDZ (Cytarabine); 5UP30YED7N (Mitobronitol); 6PLQ3CP4P3 (Etoposide); RYH2T97J77 (ranimustine); X6Q56QN5QC (Hydroxyurea)
[Em] Mês de entrada:0702
[Cu] Atualização por classe:171109
[Lr] Data última revisão:
171109
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:061226
[St] Status:MEDLINE


  3 / 50 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:11408706
[Au] Autor:Barta A; Dénes R; Masszi T; Reményi P; Bátai A; Torbágyi E; Sipos A; Lengyel L; Jakab K; Gyódi E; Réti M; Földi J; Páldi-Haris P; Avalos M; Pálóczi K; Fekete S; Török J; Hoffer I; Jakab J; Váradi G; Kelemen E; Petrányi G
[Ad] Endereço:National Institute of Hematology and Immunology, Budapest, Hungary.
[Ti] Título:Remarkably reduced transplant-related complications by dibromomannitol non-myeloablative conditioning before allogeneic bone marrow transplantation in chronic myeloid leukemia.
[So] Source:Acta Haematol;105(2):64-70, 2001.
[Is] ISSN:0001-5792
[Cp] País de publicação:Switzerland
[La] Idioma:eng
[Ab] Resumo:A non-myeloablative conditioning protocol containing dibromomannitol (DBM/cytosine arabinoside/cyclophosphamide) has been applied to 36 chronic myeloid leukemia (CML) patients followed by bone marrow transplantation (BMT) from sibling donors. Risk factors include: accelerated phase (10 patients), older age (17 patients over >40 years) and long interval between diagnosis and BMT (27 months on average). Severe mucositis did not occur. Venoocclusive liver disease was absent. Infectious complications were rare. Although grade II-IV acute graft-versus-host disease (GVHD) was present in 9 (25%) cases, there were only 2 serious (III-IV) ones. Chronic GVHD occurred in 25 (69%) cases, preceded by acute GVHD in 9 of the 25 affected patients. Early hematological relapse, 7-29 weeks after BMT, developed in 6 patients (17.6%). No relapse was noted in the completely chimeric patients, however molecular genetic residual disease was observed in 6 patients, in most of them after transient short-term mixed chimeric state. Overall actual survival rate is 83.3% for the 36 cases, and leukemia-free survival is 72.2% for the 34 engrafted patients.
[Mh] Termos MeSH primário: Transplante de Medula Óssea/métodos
Leucemia Mielogênica Crônica BCR-ABL Positiva/tratamento farmacológico
Mitobronitol/administração & dosagem
Condicionamento Pré-Transplante/métodos
[Mh] Termos MeSH secundário: Adolescente
Adulto
Idoso
Antineoplásicos Alquilantes/administração & dosagem
Antineoplásicos Alquilantes/normas
Antineoplásicos Alquilantes/toxicidade
Transplante de Medula Óssea/normas
Causas de Morte
Intervalo Livre de Doença
Feminino
Doença Enxerto-Hospedeiro
Seres Humanos
Leucemia Mielogênica Crônica BCR-ABL Positiva/complicações
Leucemia Mielogênica Crônica BCR-ABL Positiva/terapia
Masculino
Meia-Idade
Mitobronitol/normas
Mitobronitol/toxicidade
Taxa de Sobrevida
Quimeras de Transplante
Condicionamento Pré-Transplante/normas
Transplante Homólogo/métodos
[Pt] Tipo de publicação:CLINICAL TRIAL; JOURNAL ARTICLE; MULTICENTER STUDY; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Antineoplastic Agents, Alkylating); 5UP30YED7N (Mitobronitol)
[Em] Mês de entrada:0107
[Cu] Atualização por classe:171101
[Lr] Data última revisão:
171101
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:010616
[St] Status:MEDLINE


  4 / 50 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:10768466
[Au] Autor:Windrum P; Hull DR; Morris TC
[Ti] Título:Herb-drug interactions.
[So] Source:Lancet;355(9208):1019-20, 2000 Mar 18.
[Is] ISSN:0140-6736
[Cp] País de publicação:England
[La] Idioma:eng
[Mh] Termos MeSH primário: Antineoplásicos Alquilantes/uso terapêutico
Carvão Vegetal
Mitobronitol/uso terapêutico
Fitoterapia
Trombocitemia Essencial/sangue
Trombocitemia Essencial/tratamento farmacológico
[Mh] Termos MeSH secundário: Idoso
Idoso de 80 Anos ou mais
Interações Medicamentosas
Feminino
Seres Humanos
Contagem de Plaquetas
Falha de Tratamento
[Pt] Tipo de publicação:CASE REPORTS; COMMENT; LETTER
[Nm] Nome de substância:
0 (Antineoplastic Agents, Alkylating); 16291-96-6 (Charcoal); 5UP30YED7N (Mitobronitol)
[Em] Mês de entrada:0005
[Cu] Atualização por classe:170920
[Lr] Data última revisão:
170920
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:000418
[St] Status:MEDLINE


  5 / 50 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:10717801
[Au] Autor:Barta A; Bátai A; Kelemen E; Lengyel L; Reményi P; Sipos A; Torbágyi E; Avalos M; Fekete E; Földi J; Páldi-Haris P; Tamáska J; Gyódi E; Rajczy K; Hoffer I; Jakab J; Petrányi GG; Pálóczi K
[Ad] Endereço:National Institute of Hematology and Immunology, Budapest, Hungary.
[Ti] Título:Immunological importance of chimerism in transplantation: new conditioning protocol in BMT and the development of chimeric state.
[So] Source:Hum Immunol;61(2):101-10, 2000 Feb.
[Is] ISSN:0198-8859
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Chimerism is an exceptional immunogenetic state, characterized by the survival and collaboration of cell populations originated from two different individuals. The prerequisits to induce chimerism are immuno-suppression, myeloablation, or severe immunodeficiency of the recipients on the one side and donor originated immuno-hematopoietic cells in the graft on the other. The pathologic or special immunogenetic conditions to establish chimerism are combined with bone marrow transplantation, transfusion, and various kinds of solid organ grafting. Different types of chimerism are known including complete, mixed and mosaic, or split chimerism. There are various methods used to detect the type of chimera state, depending on the immunogenetic differences between the donor and recipient. The induction of complete or mixed chimerism is first determinated by the effect of myeloablative therapy. The chimera state seems to be one of the leading factors to influence the course of the post-transplant period, the frequency and severity of GVHD, and the rate of relapse. However, the most important contribution of the chimeric state is in development of graft versus leukemia effect. A new conditioning protocol (DBM/Ara-C/Cy) for allogeneic BMT in CML patients and its consequence on chimera state and GVL effect is demonstrated.
[Mh] Termos MeSH primário: Transplante de Medula Óssea/imunologia
Quimeras de Transplante/imunologia
[Mh] Termos MeSH secundário: Antineoplásicos Alquilantes/farmacologia
Ciclofosfamida/farmacologia
Citarabina/farmacologia
Doença Enxerto-Hospedeiro/imunologia
Seres Humanos
Imunossupressores/farmacologia
Leucemia Mielogênica Crônica BCR-ABL Positiva/terapia
Mitobronitol/farmacologia
Quimeras de Transplante/efeitos dos fármacos
Resultado do Tratamento
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T; REVIEW
[Nm] Nome de substância:
0 (Antineoplastic Agents, Alkylating); 0 (Immunosuppressive Agents); 04079A1RDZ (Cytarabine); 5UP30YED7N (Mitobronitol); 8N3DW7272P (Cyclophosphamide)
[Em] Mês de entrada:0004
[Cu] Atualização por classe:131121
[Lr] Data última revisão:
131121
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:000316
[St] Status:MEDLINE


  6 / 50 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:9745304
[Au] Autor:Kelemen E; Dénes R; Barta A; Masszi T; Reményi P; Pálóczi K; Bátai A; Torbágyo E; Sipos A; Lengyel L; Jakab K; Gyódi E; Réti M; Földi J; Páldi-Haris P; Manuel A; Fekete S; Török J; Hoffer I; Jakab J; Váradi G; Petrányi G
[Ad] Endereço:Országos Hematológiai és Immunológiai Intézet Budapest.
[Ti] Título:[A new radiation-free conditioning in bone marrow transplantation and dibromo-mannitol therapy in chronic myeloid leukemia].
[Ti] Título:Uj, sugárzásmentes csontvelö-transzplantációs kondicionáló kezelés dibróm-mannitollal krónikus myeloid leukaemiában..
[So] Source:Orv Hetil;139(34):2003-1; discussion 2011-2, 1998 Aug 23.
[Is] ISSN:0030-6002
[Cp] País de publicação:Hungary
[La] Idioma:hun
[Ab] Resumo:A new, radiation-free, conditioning protocol, containing the original Hungarian mitobronitol (DBM) (DBM/ cytosine arabinoside/cyclosphosphamide) has been applied to 36 chronic myeloid leukemia (CML) patients followed by bone marrow transplantation (BMT) from HLA identical sibling donors between 1990-1997. In spite of some prognostically disadvantageous factors (half of them were above 40 years, 10 out of 36 patients were in accelerated phase, the disease history was longer than 2 years in average) the overall survival (30/36) and the leukemia free survival rate (26/36) were in accordance with the best international results. Transplantation-related toxicity was remarkably reduced in comparison to bone marrow transplantation performed by total body irradiation/cyclophosphamide (TBI/Cy) or busulphan/cyclophosphamide (Bu/Cy) conditioning protocols. Acute graft versus host disease was present in lower percentage (9/36) and the number of serious cases was only 2/36. Chronic GVH disease, generally known to be associated with antileukemic effect (GVL), occurred in 25 of cases. Early haematological relapse among the 34 patients with functioning graft occurred in 6 patients which rate is slightly higher than reported after TBI/Cy or Bu/Cy conditioning treatment. There was no relapse among patients transplanted within one year post-diagnosis and patients having CML with accelerated phase. The leukemia free post-transplant period was in association with the chronic GVH disease and full chimeric state.
[Mh] Termos MeSH primário: Transplante de Medula Óssea
Leucemia Mielogênica Crônica BCR-ABL Positiva/terapia
Mitobronitol/uso terapêutico
[Mh] Termos MeSH secundário: Adolescente
Adulto
Protocolos Clínicos
Feminino
Reação Enxerto-Hospedeiro/efeitos dos fármacos
Seres Humanos
Masculino
Meia-Idade
[Pt] Tipo de publicação:ENGLISH ABSTRACT; JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
5UP30YED7N (Mitobronitol)
[Em] Mês de entrada:9809
[Cu] Atualização por classe:131121
[Lr] Data última revisão:
131121
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:980924
[St] Status:MEDLINE


  7 / 50 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:9603396
[Au] Autor:Kelemen E; Masszi T; Reményi P; Barta A; Pálóczi K
[Ad] Endereço:National Institute of Hematology and Immunology, Budapest, Hungary.
[Ti] Título:Reduction in the frequency of transplant-related complications in patients with chronic myeloid leukemia undergoing BMT preconditioned with a new, non-myeloablative drug combination.
[So] Source:Bone Marrow Transplant;21(8):747-9, 1998 Apr.
[Is] ISSN:0268-3369
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:A radiation-free, non-myeloablative, myelosuppressive protocol, containing dibromomannitol and cytosine arabinoside, that remarkably reduced the frequency of transplant-related complications, such as veno-occlusive liver disease (VOLD), severe mucositis, bacterial sepsis, hemorrhagic cystitis, interstitial pneumonitis, has been applied in 19 CML patients, allotransplanted from identical siblings. Five patients were in accelerated phase. Acute GVHD developed in two patients and chronic GVHD occurred in 66% of patients. Follow-up was 3 to 7 1/2 years. Although only eight patients were under 30 years of age, and only two patients had a history of less than 1 year, the leukemia-free survival was 82%. There were four hematological relapses. The reduction in post-BMT complications has greatly enhanced quality of life. The nurses reported significant reduction of work-load. Savings in eliminating the need for irradiation, parenteral nutrition, and several antibiotics are also remarkable. The remarkable reduction of certain transplant-related complications shows some advantage against busulphan-preconditioning.
[Mh] Termos MeSH primário: Antineoplásicos Alquilantes/uso terapêutico
Transplante de Medula Óssea/efeitos adversos
Leucemia Mielogênica Crônica BCR-ABL Positiva/terapia
Mitobronitol/uso terapêutico
Condicionamento Pré-Transplante
[Mh] Termos MeSH secundário: Adulto
Doença Enxerto-Hospedeiro/prevenção & controle
Hepatopatia Veno-Oclusiva/prevenção & controle
Seres Humanos
Meia-Idade
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Antineoplastic Agents, Alkylating); 5UP30YED7N (Mitobronitol)
[Em] Mês de entrada:9807
[Cu] Atualização por classe:131121
[Lr] Data última revisão:
131121
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:980529
[St] Status:MEDLINE


  8 / 50 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:9324299
[Au] Autor:Szebeni J; Barna K; Uher F; Milosevits J; Pálóczi K; Gaál D; Petrányi GG; Kelemen E
[Ad] Endereço:National Institute of Hematology and Immunology, Budapest, Hungary.
[Ti] Título:Comparison of the lymphoid toxicities of mitobronitol and busulphan in mice: reduced B cell toxicity and improved thymic recovery as possible contributors to the reduced risk for complications following BMT with mitobronitol preconditioning.
[So] Source:Leukemia;11(10):1769-74, 1997 Oct.
[Is] ISSN:0887-6924
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:It has previously been reported that the use of mitobronitol (dibromomannitol, DBM) instead of busulphan (BU) for myelosuppression is associated with significantly decreased risk for several complications of allogeneic bone marrow transplantation in accelerated chronic granulocytic leukemia. In exploring the pharmacologic basis for this observation, we have compared the acute and subacute cytotoxicities of DBM and BU on the spleen and thymus of mice. While there was comparable early (day 3) weight loss in both organs following these treatments, splenic B cells exhibited significantly less damage, and thymic regeneration (over weeks) was significantly faster following DBM treatment than with BU. These observations raise the possibility that improved post-BMT immune recovery could contribute to the clinical benefits observed with DBM-preconditioning.
[Mh] Termos MeSH primário: Antineoplásicos Alquilantes/toxicidade
Linfócitos B/efeitos dos fármacos
Purging da Medula Óssea/efeitos adversos
Transplante de Medula Óssea/efeitos adversos
Bussulfano/toxicidade
Mitobronitol/toxicidade
Timo/efeitos dos fármacos
[Mh] Termos MeSH secundário: Animais
Feminino
Camundongos
Camundongos Endogâmicos BALB C
Fatores de Risco
Baço/citologia
Baço/efeitos dos fármacos
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Antineoplastic Agents, Alkylating); 5UP30YED7N (Mitobronitol); G1LN9045DK (Busulfan)
[Em] Mês de entrada:9710
[Cu] Atualização por classe:131121
[Lr] Data última revisão:
131121
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:971027
[St] Status:MEDLINE


  9 / 50 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:8586763
[Au] Autor:Tsuji T
[Ad] Endereço:Department of Dermatology, Nagoya City University Medical School, Japan.
[Ti] Título:Erythemas associated with essential thrombocythemia.
[So] Source:J Dermatol;22(10):788-94, 1995 Oct.
[Is] ISSN:0385-2407
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:Two cases of erythemas associated with essential thrombocythemia (ET) are reported. Case 1: A 64-year-old woman, whose ET had been treated with myebronitol for about 10 years, developed erythematous plaques on her trunk after she stopped taking the medicine. Case 2: A 58-year-old man, who had had gallstones and ET, developed annular erythemas on his thighs, arms, and trunk. Operation for the gallstones had no effect on the eruption. In both cases, remission of thrombocythemia induced by myebronitol was associated with the disappearance of these erythemas.
[Mh] Termos MeSH primário: Eritema/etiologia
Mitobronitol/uso terapêutico
Trombocitemia Essencial/complicações
[Mh] Termos MeSH secundário: Colelitíase/complicações
Colelitíase/terapia
Eritema/patologia
Feminino
Seres Humanos
Litotripsia
Masculino
Meia-Idade
Mitobronitol/administração & dosagem
Trombocitemia Essencial/tratamento farmacológico
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE
[Nm] Nome de substância:
5UP30YED7N (Mitobronitol)
[Em] Mês de entrada:9603
[Cu] Atualização por classe:131121
[Lr] Data última revisão:
131121
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:951001
[St] Status:MEDLINE


  10 / 50 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
[PMID]:7762799
[Au] Autor:Cserháti T
[Ad] Endereço:Central Research Institute for Chemistry, Hungarian Academy of Sciences, Budapest.
[Ti] Título:Charge-transfer chromatographic study of the complex formation of some anticancer drugs with gamma-cyclodextrin.
[So] Source:Anal Biochem;225(2):328-32, 1995 Mar 01.
[Is] ISSN:0003-2697
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:The interaction between 23 anticancer drugs and gamma-cyclodextrin (gamma-CD) was studied by reversed-phase charge-transfer thin-layer chromatography and the relative strength of interaction was calculated. gamma-CD formed inclusion complexes with 14 compounds, the complex always being more or less hydrophobic than the uncomplexed drug. The inclusion-forming capacity of a drug differed considerably depending on its chemical structure. The linear correlation between the hydrophobicity and the specific hydrophobic surface area of anticancer drugs indicated that they can be considered a homologous series of compounds, although their chemical structures are highly different.
[Mh] Termos MeSH primário: Antineoplásicos/química
Ciclodextrinas/química
gama-Ciclodextrinas
[Mh] Termos MeSH secundário: Antineoplásicos/farmacologia
Carboplatina/química
Carboplatina/farmacologia
Cromatografia/métodos
Ciclodextrinas/metabolismo
Mesilatos/química
Mesilatos/farmacologia
Mitobronitol/química
Mitobronitol/farmacologia
Relação Estrutura-Atividade
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Antineoplastic Agents); 0 (Cyclodextrins); 0 (Mesylates); 0 (gamma-Cyclodextrins); 135FQ40L36 (mannosulfan); 5UP30YED7N (Mitobronitol); BG3F62OND5 (Carboplatin); KZJ0BYZ5VA (gamma-cyclodextrin)
[Em] Mês de entrada:9506
[Cu] Atualização por classe:141120
[Lr] Data última revisão:
141120
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:950301
[St] Status:MEDLINE



página 1 de 5 ir para página              
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde